- Home
- COE vs ACRS Comparison
COE vs ACRS Comparison
Compare COE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- ACRS
- Stock Information
- Founded
- COE 2011
- ACRS 2012
- Country
- COE Singapore
- ACRS United States
- Employees
- COE N/A
- ACRS 64
- Industry
- COE Other Consumer Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- ACRS Health Care
- Exchange
- COE Nasdaq
- ACRS Nasdaq
- Market Cap
- COE 112.7M
- ACRS 137.5M
- IPO Year
- COE 2016
- ACRS 2015
- Fundamental
- Price
- COE $19.80
- ACRS $1.46
- Analyst Decision
- COE
- ACRS Strong Buy
- Analyst Count
- COE 0
- ACRS 8
- Target Price
- COE N/A
- ACRS $9.71
- AVG Volume (30 Days)
- COE 6.2K
- ACRS 709.4K
- Earning Date
- COE 06-11-2025
- ACRS 05-08-2025
- Dividend Yield
- COE N/A
- ACRS N/A
- EPS Growth
- COE N/A
- ACRS N/A
- EPS
- COE N/A
- ACRS N/A
- Revenue
- COE $50,692,000.00
- ACRS $17,777,000.00
- Revenue This Year
- COE N/A
- ACRS N/A
- Revenue Next Year
- COE N/A
- ACRS $14.59
- P/E Ratio
- COE N/A
- ACRS N/A
- Revenue Growth
- COE 86.98
- ACRS N/A
- 52 Week Low
- COE $6.65
- ACRS $0.99
- 52 Week High
- COE $25.70
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- COE 58.42
- ACRS 61.33
- Support Level
- COE $17.90
- ACRS $1.22
- Resistance Level
- COE $19.89
- ACRS $1.56
- Average True Range (ATR)
- COE 0.62
- ACRS 0.09
- MACD
- COE 0.00
- ACRS 0.03
- Stochastic Oscillator
- COE 95.00
- ACRS 75.00
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.